Lysosomal degradation of PD-L1 is associated with immune-related adverse events during anti-PD-L1 immunotherapy in NSCLC patients

• Main Authors: Takeru Kashiwada (Author), Ryotaro Takano (Author), Fumihiko Ando (Author), Shoko Kuroda (Author), Yoshishige Miyabe (Author), Ryuji Owada (Author), Akihiko Miyanaga (Author), Tomoko Asatsuma-Okumura (Author), Masaaki Hashiguchi (Author), Yoshikazu Kanazawa (Author), Hiroshi Yoshida (Author), Masahiro Seike (Author), Akihiko Gemma (Author), Yoshiko Iwai (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Immune checkpoint inhibitors (ICIs) can induce immune-related adverse events (irAEs). Liquid biomarkers to predict irAE occurrence are urgently needed. We previously developed an ELISA system to specifically detect soluble PD-L1 (sPD-L1) with PD-1-binding capacity (bsPD-L1). Here, we inv...